Fig. 5

USP11 is downregulated and correlates with PTEN in human cancers. a, b USP11 expression in human prostate (a) and breast (b) cancers using a previously published microarray database. Stephenson’s CaP, prostate carcinoma (ref.⁴⁴, n = 97); Taylor’s CaP (GEO: GSE21032, n = 179); Liu’s BCa, breast carcinoma (GEO: GSE22820, n = 176). The line in the middle, upper end, and lower end of the boxplot represents the mean, upper, and lower quartile of the relative mRNA level of all samples, respectively. The lines above and below the box are the maximum and minimum values. Data points beyond the whiskers ( > 1.5 interquartile ranges) are drawn as individual dots. Error bars represent ±  SEM. p Value was determined by Student’s t test (**p < 0.01; ***p < 0.001). c Online analysis of relapse-free survival (RFS) (n = 618) and overall survival (OS) (n = 241) in human basal-type breast cancer patients with high or low USP11 expression. The number of surviving patients at different time points is indicated below the graphs. p Value was determined by log-rank (Mantel–Cox) test. HR, hazard ratio. d Fluorescence in situ hybridization (FISH) analysis of PTEN in human prostate (left, n = 116) and TNBC (right, n = 103) tumor samples. The table indicates the frequency of PTEN immunohistochemical (IHC) status by PTEN FISH status. Correlation between PTEN IHC and PTEN FISH was determined by the PASS Pearson Chi-square test. e IHC analysis of USP11 and PTEN in human prostate (top, n = 99) and TNBC (bottom, n = 86) tumor samples (left). Scale bars, 50μm. Correlation between USP11 and PTEN protein levels was determined by the PASS Pearson Chi-square test (right). r, correlation coefficient. TNBC, triple-negative breast cancer